This is a non-interventional study using real-world retrospective efficacy (CDR-SB) data from prescribing institutions in North America to evaluate the efficacy of LEQEMBI.
As this is a Retrospective Database Study, the Study Start Date for this study references the date at which the first set of data will become available.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant (or legally authorized representative) has provided written informed consent to participate in the local site registry
Mild cognitive impairment (MCI) due to AD or mild AD dementia, according to the National Institute on Aging - Alzheimer's Association (NIA-AA) criteria
Global CDR at baseline of 0.5 or 1
APOE4 heterozygous or noncarrier
Have had a baseline CDR-SB (before initiation of LEQEMBI treatment)
Completed 18 months of LEQEMBI treatment, with an 18-month CDR-SB assessment
You may not be if
Use of any other anti-amyloid treatment prior to and during the 18-month LEQEMBI treatment period
Conditions highlighted under "Contraindications" section in the Canadian Product Monograph
